Intuit stock rises on upbeat full-year forecast amid a pivot toward AI

Date:

Share post:




Tax-preparation software provider Intuit Inc. on Thursday forecast profit and sales for the fiscal year ahead that were above Wall Street’s expectations, although its first-quarter outlook came up short, as it tries to prepare for a world of AI-driven financial assistance.



Source link

Alexandra Williams
Alexandra Williams
Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

Recent posts

Related articles

Trump’s choice of Dr. Oz to oversee Medicare and Medicaid could be ‘devastating’ for millions of Americans

The selection of television personality Dr. Mehmet Oz to run the Centers for Medicare and Medicaid Services...

Buy gold after its pullbacks — because it may hit $3,000 in 2025

Gold prices have been showing signs of life against a backdrop of worrisome headlines tied to the...

Bitcoin sits near record high. More good news for investors: It’s now less volatile. 

With bitcoin touching all-time highs again, investors are more confident that the latest bull run will be...

RFK Jr. may start a food and drug ‘culture war.’ Investors are running for cover.

President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human...

Here’s what bond and gold traders are signaling about Russia’s nuclear shift

Traditional flight-to-safety trades took off on Tuesday in response to a worsening conflict between Russia and Ukraine,...

Stock market ‘finally paying more attention to tariffs’ as a potential headwind

Tariffs have taken the spotlight as a policy issue as S&P 500 companies have discussed earnings with...

Investors are bracing for higher-for-even-longer interest rates

Friday’s stronger-than-expected economic data, combined with fresh remarks from Federal Reserve Chairman Jerome Powell on Thursday, were...

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs...